Accessibility StatementSkip Navigation EirGenix has successfully utilized reverse engineering technologies to develop multiple biosimilar products. This new agreement underscores EirGenix's global competitiveness, technical excellence, and internationalization capabilities. With regulatory trends increasingly favorable, EirGenix is accelerating the development of four HER2-targeted antibody programs, expanding its in-house product pipeline as well as CDMO services for additional biosimilar projects. As glob ...